ProQR Therapeutics (NASDAQ:PRQR) Receives "Buy" Rating from Chardan Capital

Chardan Capital restated their buy rating on shares of ProQR Therapeutics (NASDAQ:PRQR - Free Report) in a report released on Friday, Benzinga reports. The brokerage currently has a $2.50 price target on the biopharmaceutical company's stock.

A number of other equities research analysts also recently weighed in on PRQR. StockNews.com downgraded ProQR Therapeutics from a buy rating to a hold rating in a research report on Tuesday, March 19th. HC Wainwright restated a buy rating and issued a $5.00 price target on shares of ProQR Therapeutics in a report on Friday. Finally, Citigroup boosted their price objective on shares of ProQR Therapeutics from $1.80 to $2.00 and gave the stock a buy rating in a research note on Thursday, April 18th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and a consensus price target of $3.60.

ProQR Therapeutics Stock Down 1.0 %

Shares of NASDAQ:PRQR traded down $0.02 during trading hours on Friday, hitting $1.98. The company's stock had a trading volume of 181,113 shares, compared to its average volume of 162,860. The firm's fifty day moving average price is $2.13 and its 200 day moving average price is $1.95. ProQR Therapeutics has a 52 week low of $1.11 and a 52 week high of $3.29. The company has a market capitalization of $161.09 million, a price-to-earnings ratio of -5.08 and a beta of 0.30. The company has a debt-to-equity ratio of 0.10, a current ratio of 3.54 and a quick ratio of 3.54.

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) last issued its quarterly earnings data on Wednesday, March 13th. The biopharmaceutical company reported ($0.08) EPS for the quarter, hitting analysts' consensus estimates of ($0.08). The company had revenue of $3.54 million during the quarter, compared to the consensus estimate of $27.88 million. ProQR Therapeutics had a negative net margin of 431.65% and a negative return on equity of 56.71%. As a group, research analysts expect that ProQR Therapeutics will post -0.37 EPS for the current year.

Institutional Trading of ProQR Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Monaco Asset Management SAM boosted its holdings in ProQR Therapeutics by 58.9% during the third quarter. Monaco Asset Management SAM now owns 377,517 shares of the biopharmaceutical company's stock worth $491,000 after buying an additional 140,000 shares in the last quarter. BNP Paribas Financial Markets raised its position in shares of ProQR Therapeutics by 120.1% in the first quarter. BNP Paribas Financial Markets now owns 35,001 shares of the biopharmaceutical company's stock worth $80,000 after acquiring an additional 19,100 shares during the period. RFG Advisory LLC purchased a new stake in shares of ProQR Therapeutics during the 1st quarter worth about $73,000. Finally, Acadian Asset Management LLC purchased a new stake in shares of ProQR Therapeutics during the 1st quarter worth about $56,000. Institutional investors and hedge funds own 32.65% of the company's stock.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).